A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

For the current fiscal year, ending in December 2025, analysts expect Regeneron’s EPS to decline nearly 7% year over year to $35.92. The company’s earnings surprise history is mixed.

Regeneron (REGN) announced updated data for ... and corroborated with positive auditory brainstem responses. The company said particularly encouraging were results from formal speech perception ...

Regeneron’s fund will be independently managed by former Regeneron executives Jay Markowitz and Michael Aberman, said the company, which said the primary interest of the new fund is in ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Regeneron and Illumina have joined a major ... of genotypic and phenotypic information ever assembled," claims the company. It will tap into Truveta's platform – based on electronic medical ...

Commissions do not affect our editors' opinions or evaluations. One of the most important decisions small business owners face is choosing the right business banking relationship. For many ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our ...

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S ...

Commissions do not affect our editors' opinions or evaluations. The best business credit cards offer a range of benefits, including rewards or cash back, purchase protections and expense ...